News & Events

2006...

NEW YORK, NY and BOOTHWYN, PA, October 6 - WIL Research Holding Company, Inc. and Behrman Capital are pleased to announce the completion of an agreement whereby WIL Research Holding Company, Inc. has acquired QS Pharma as part of a management buyout for an undisclosed sum. QS Pharma is a US, Pennsylvania based, privately held contract research organization (CRO) specializing in providing services to develop and produce stable, oral dosage forms for use in early phase preclinical drug development, clinical trials and regulatory submissions.

"The acquisition of QS Pharma strengthens our commitment to the early development CRO space," said Roy Dagnall, Ph.D., chief executive officer for WIL Research Holding Company, Inc. "The addition of QS Pharma to WIL Research Laboratories, LLC., Notox B.V. and Biotechnics, Inc. provides new expertise to assist clients with formulation development and production of dosage forms for accelerating the time required to early phase clinical trials."

QS Pharma's co-founders Madurai Ganesan, Ph.D., president and Michael Maurin, Ph.D., vice president commented "We are delighted to be joining such a successful, high quality contract research group with ambitious plans. We are very excited to be part of a larger organization that will help fuel further growth at QS Pharma." Both Madurai Ganesan and Michael Maurin will remain in their current positions.

Behrman Capital has made significant internal and external investments in the WIL Holding companies, including the latest acquisition of QS Pharma. This has resulted in a strategic CRO portfolio offering high quality, scientifically driven, complementary toxicology and drug formulation services on a global basis to best serve the pharmaceutical, biotechnology and chemical industries.

2005..

For the third consecutive year, Dr. Michael B. Maurin, Vice President and Cofounder of QS Pharma was honored recently by the Editor, Publisher (Wiley Interscience) and sponsoring professional associate (American Pharmaceutical Association) of the Journal of Pharmaceutical Sciences for outstanding contributions as a reviewer to the Journal of Pharmaceutical Sciences in 2005.